Fact Sheet

The Cost of 340B to **West Virginia**

In 2025, workers and employers lost $157 million in negotiated rebates to 340B

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost $14.5 billion in rebates nationally in 2025 due to 340B.[1] The cost to West Virginia workers and employers in 2025 was $157 million.

Cost of 340B to West Virginia workers and employers

PER BENEFICIARY	PLAN TYPE	TOTAL COST
$193	Private sector employees[2]	**$131M**
	Government employees[3]	**$26M**
	Total	**$157M**

The cost of 340B to West Virginia has increased substantially in recent years due to program growth. From 2023 to 2025, the number of healthcare providers prescribing 340B drugs, the number of 340B facilities, and the value of 340B drug purchases all increased.

340B growth in West Virginia: 2023 to 2025

340B PRESCRIBERS		340B FACILITIES[4]		340B DRUG PURCHASES[5]	
#	GROWTH	#	GROWTH	#	GROWTH
15,140	+12%	590	+9%	$1.9 billion	+36%

Compared to its neighboring states, West Virginia has disproportionately high 340B utilization and hence cost.

West Virginia vs. neighbors

STATE	340B UTILIZATION[6]	COST PER BENEFICIARY
WV	34%	$193
VA	12%	$69
OH	16%	$90
KY	21%	$121
Total U.S.	**14%**	**$81**

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.

CONTACT US

iqvia.com